Results · Apr-Jun 2026
Aurobindo Pharma Q1 FY27 results
Very strongVery strong: sales up 15% or more & profit up 25% or more on the same quarter last year, with a wider operating margin.
Sales grew 16% to ₹9,150 crore from ₹7,868 crore in Apr-Jun 2025.
Operating profit grew 17% to ₹1,881 crore, an operating margin of 20.6% (up 0.2 points from a year ago).
Net profit grew 25% to ₹1,032 crore from ₹824 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +3%, net profit +12%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 9,150 | 7,868 | +16% |
| Operating profit (EBITDA) | 1,881 | 1,603 | +17% |
| Operating margin | 20.6% | 20.4% | +0.2 pts |
| Net profit | 1,032 | 824.2 | +25% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.